Catherine Moukheibir - 03 Jul 2025 Form 4 Insider Report for MoonLake Immunotherapeutics (MLTX)

Role
Director
Signature
/s/ Matthias Bodenstedt, Attorney-in-fact for Catherine Moukheibir
Issuer symbol
MLTX
Transactions as of
03 Jul 2025
Net transactions value
-$1,146,565
Form type
4
Filing time
07 Jul 2025, 16:03:16 UTC
Previous filing
12 Jun 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Moukheibir Catherine Director C/O MOONLAKE IMMUNOTHERAPEUTICS, DORFSTRASSE 29, ZUG, SWITZERLAND /s/ Matthias Bodenstedt, Attorney-in-fact for Catherine Moukheibir 07 Jul 2025 0001772130

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MLTX Class A ordinary shares, par value $0.0001 per share Options Exercise $0 +23,500 $0.000000 23,500 03 Jul 2025 Direct
transaction MLTX Class A ordinary shares, par value $0.0001 per share Sale $1,146,565 -23,500 -100% $48.79 0 03 Jul 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MLTX Option to Buy Options Exercise $0 -23,500 -52% $0.000000 21,500 03 Jul 2025 Class A ordinary shares, par value $0.0001 per share 23,500 $12.25 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $48.59 to $49.01. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F2 These options are fully vested.